Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. A third of psoriatic patients develop PsA via unknown mechanisms. No reliable diagnostic markers are available for PsA, or prognostic biomarkers for PsA development in psoriasis. We previously uncovered a pro-inflammatory role for cathelicidin LL37 in lesional psoriasis skin. LL37 binds nucleic acids and stimulates plasmacytoid/myeloid dendritic cells (pDC, mDCs) to secrete type I interferon (IFN-I) and pro-inflammatory factors. LL37 becomes an autoantigen for psoriatic Th1-Th17/CD8 T cells. Anti-LL37 antibodies were detected in systemic lupus erythematosus, an autoimmune disease characterized by neutrophil-extracellular-traps release (NETosis) in target organs. LL37 can be substrate of irreversible post-translational modifications, citrullination or carbamylation, linked to neutrophil activity. Here we analyzed inflammatory factors, included LL37, in PsA and psoriasis plasma and PsA synovial fluids (SF)/biopsies. We show that LL37 (as a product of infiltrating neutrophils) and autoantibodies to LL37 are elevated in PsA, but not OA SF. Anti-LL37 antibodies correlate with clinical inflammatory markers. Anti-carbamylated/citrullinated-LL37 antibodies are present in PsA SF/plasma and, at lower extent, in psoriasis plasma, but not in controls. Plasma anti-carbamylated-LL37 antibodies correlate with PsA (DAS44) but not psoriasis (PASI) disease activity. Ectopic lymphoid structures, and deposition of immunoglobulin-(Ig)G-complexes (IC) co-localizing with infiltrating neutrophils, are observed in PsA and not OA synovial tissues (ST). Activated complement (C5a, C9), GM-CSF and IFN-I are up-regulated in PsA and not OA synovia and in PsA and psoriasis plasma but not in HD. C9 and GM-CSF levels in PsA SF correlate with clinical inflammatory markers and DAS44 (C9) and with anti-carbamylated/citrullinated-LL37 antibodies (GM-CSF and IFN-I). Thus, we uncover a role for LL37 as a novel PsA autoantibody target and correlation studies suggest participation of anti-LL37 antibodies to PsA pathogenesis. Notably, plasma antibodies to carbamylated-LL37, which correlate with DAS44, suggest their use as new disease activity markers. GM-CSF and complement C5a and C9 elevation may be responsible for autoantigens release by neutrophils and their modification, fueling inflammation and autoreactivity establishment. Finally, targeting GM-CSF, C5a, C9 can be beneficial in PsA.
Frasca, L., Palazzo, R., Chimenti, M.s., Alivernini, S., Tolusso, B., Bui, L., et al. (2018). Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA. FRONTIERS IN IMMUNOLOGY, 9(SEP), 1936.
|Tipologia:||Articolo su rivista|
|Citazione:||Frasca, L., Palazzo, R., Chimenti, M.s., Alivernini, S., Tolusso, B., Bui, L., et al. (2018). Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA. FRONTIERS IN IMMUNOLOGY, 9(SEP), 1936.|
|IF:||Con Impact Factor ISI|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
Settore MED/35 - Malattie Cutanee e Veneree
|Revisione (peer review):||Esperti anonimi|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3389/fimmu.2018.01936|
|Stato di pubblicazione:||Pubblicato|
|Data di pubblicazione:||2018|
|Titolo:||Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA|
|Autori:||Frasca, L; Palazzo, R; Chimenti, Ms; Alivernini, S; Tolusso, B; Bui, L; Botti, E; Giunta, A; Bianchi, L; Petricca, L; Auteri, Se; Spadaro, F; Fonti, Gl; Falchi, M; Evangelista, A; Marinari, B; Pietraforte, I; Spinelli, Fr; Colasanti, T; Alessandri, C; Conti, F; Gremese, E; Costanzo, A; Valesini, G; Perricone, R; Lande, R|
|Appare nelle tipologie:||01 - Articolo su rivista|